# A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy

> **NCT06848231** · PHASE2 · RECRUITING · sponsor: **Dasher Neuroscience Inc.** · enrollment: 75 (estimated)

## Conditions studied

- Multiple System Atrophy

## Interventions

- **DRUG:** YA-101
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06848231
- **Lead sponsor:** Dasher Neuroscience Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-03
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06848231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06848231, "A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06848231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*